Standard treatment and emerging drugs for managing synovial sarcoma: adult’s and pediatric oncologist perspective

References

• Ferrari A, Bisogno G, Meazza C, et al. The challenge of access to care for soft tissue sarcomas bridging pediatric and adult age: the Italian pediatric oncology view. Expert Rev Anticancer Ther. 2012;12(2):243–254.
   PubMed Web of Science ®Google Scholar
• Ferrari A, Sultan I, Huang TT, et al. Soft tissue sarcoma across the age spectrum: a population-based study from the surveillance epidemiology and end results database. Pediatr Blood Cancer. 2011;57:943–949.
   PubMed Web of Science ®Google Scholar
• Sultan I, Rodriguez-Galindo C, Saab R, et al. Comparing children and adults with synovial sarcoma in the surveillance, epidemiology and end results program, 1983 to 2005: an analysis of 1268 patients. Cancer. 2009;115:3537–3547.
   PubMed Web of Science ®Google Scholar
• Ferrari A, Chiaravalli S, Casanova M, et al. Considering chemotherapy in synovial sarcoma. Expert Opin Orphan Drugs. 2015;3(10):1111–1124.
   Web of Science ®Google Scholar
• Ferrari A, Casanova M. Relapse in synovial sarcoma: what can be done for poor outcomes? Clin. Pract. 2013;10(4):1–3.
   Google Scholar
• Ferrari A, Casanova M. New concepts for the treatment of pediatric non-rhabdomyosarcoma soft tissue sarcomas. Expert Rev Anticancer Ther. 2005;5(2):307–318.
   PubMed Web of Science ®Google Scholar
• Ferrari A, Bleyer A, Patel S, et al. The challenge of the management of adolescents and young adults with soft tissue sarcomas. Pediatr Blood Cancer. 2018 Jul;65(7):e27013.
   PubMed Web of Science ®Google Scholar
• Ferrari A, De Salvo GL, Dall’Igna P, et al. Salvage rates and prognostic factors after relapse in children and adolescents with initially localised synovial sarcoma. Eur J Cancer. 2012;48:3448–3455.
   PubMed Web of Science ®Google Scholar
• Guillou L, Benhattar J, Bonichon F, et al. Histologic grade, but not SS18-SSX fusion type, is an important prognostic factor in patients with synovial sarcoma: A multicenter, retrospective analysis. J Clin Oncol. 2004;22:4040–4050.
   PubMed Web of Science ®Google Scholar
• Van der Graaf WTA, Orbach D, Judson IR, et al. Soft tissue sarcomas in adolescents and young adults: a comparison with their paediatric and adult counterparts. Lancet Oncol. 2017 Mar;18(3):e166–e175.
   PubMed Web of Science ®Google Scholar
• Ferrari A, De Salvo GL, Oberlin O, et al. Synovial sarcoma in children and adolescents: A critical reappraisal of staging investigations in relation to the rate of metastatic involvement at diagnosis. Eur J Cancer. 2012;48:1370–1375.
   PubMed Web of Science ®Google Scholar
• Ferrari A, De Salvo GL, Brennan B, et al. Synovial sarcoma in children and adolescents: the European pediatric soft tissue sarcoma study group prospective trial (EpSSG NRSTS 2005). Ann Oncol. 2015;26:567–572.
   PubMed Web of Science ®Google Scholar
• Okcu MF, Munsell M, Treuner J, et al. Synovial sarcoma of childhood and adolescence: a multicenter, multivariate analysis of outcome. J Clin Oncol. 2003;21:1602–1611.
   PubMed Web of Science ®Google Scholar
• Ferrari A, Bisogno G, Alaggio R, et al. Synovial sarcoma of children and adolescents: the prognostic role of axial sites. Eur J Cancer. 2008;44:1202–1209.
   PubMed Web of Science ®Google Scholar
• Guadagnolo BA, Zagars GK, Ballo MT, et al. Long-term outcomes for synovial sarcoma treated with conservation surgery and radiotherapy. Int J Radiat Oncol Biol Phys. 2007 Nov 15;69(4):1173–1180.
   PubMed Web of Science ®Google Scholar
• Italiano A, Penel N, Robin Y-M, et al. Neo/adjuvant chemotherapy does not improve outcome in resected primary synovial sarcoma: a study of the French sarcoma group. Ann Oncol. 2009;20(3):425–430.
   PubMed Web of Science ®Google Scholar
• Lewis JJ, Antonescu CR, Leung DH, et al. Synovial sarcoma: a multivariate analysis of prognostic factors in 112 patients with primary localized tumors of the extremity. J Clin Oncol. 2000;18:2087–2094.
   PubMed Web of Science ®Google Scholar
• Trassard M, Le Doussal V, Hacène K, et al. Prognostic factors in localized primary synovial sarcoma: a multicenter study of 128 adult patients. J Clin Oncol. 2001;19:525–534.
   PubMed Web of Science ®Google Scholar
• Palmerini E, Staals EL, Alberghini M, et al. Synovial sarcoma: retrospective analysis of 250 patients treated at a single institution. Cancer 2009;115 (13):2988–2998
   PubMed Web of Science ®Google Scholar
• Lagarde P, Przybyl J, Brulard C, et al. Chromosome instability accounts for reverse metastatic outcomes of pediatric and adult synovial sarcomas. J Clin Oncol. 2013 Feb 10;31(5):608–615.
   PubMed Web of Science ®Google Scholar
• Lesluyes T, Delespaul L, Coindre J-M, et al. The CINSARC signature as a prognostic marker for clinical outcome in multiple neoplasms. Sci Rep. 2017 Jul 14;7(1):5480.
   PubMedGoogle Scholar
• Bakhoum SF, Cantley LC. The multifaceted role of chromosomal instability in cancer and its microenvironment. Cell. 2018 Sep 6;174(6):1347–1360.
   PubMed Web of Science ®Google Scholar
• Orbach D, Mosseri V, Pissaloux D, et al. Genomic complexity in pediatric synovial sarcomas (Synobio study): the European pediatric soft tissue sarcoma group (EpSSG) experience. Cancer Med. 2018;7:1384–1393.
   PubMed Web of Science ®Google Scholar
• Chibon F, Lagarde P, Salas S, et al. Validated prediction of clinical outcome in sarcomas and multiple types of cancer on the basis of a gene expression signature related to genome complexity. Nat Med. 2010 Jul;16(7):781–787.
   PubMed Web of Science ®Google Scholar
• Bakhoum SF, Ngo B, Laughney AM, et al. Chromosomal instability drives metastasis through a cytosolic DNA response. Nature. 2018;553:467–472.
   PubMed Web of Science ®Google Scholar
• Demicco E. Cancer genome atlas research network. Comprehensive and integrated genomic characterization of adult soft tissue sarcomas. Cell. 2017 Nov 2;171(4):950–965.
   PubMed Web of Science ®Google Scholar
• Thomas DG, Giordano TJ, Sanders D, et al. Expression of receptor tyrosine kinases growth factor receptor and HER-2/neu in synovial sarcoma. Cancer. 2005;103(4):830–838.
   PubMed Web of Science ®Google Scholar
• Brien GL, Remillard D, Shi J, et al. Targeted degradation of BRD9 reverses oncogenic gene expression in synovial sarcoma. eLife. 2018;7:e41305.
   PubMed Web of Science ®Google Scholar
• Dawson MA, Kouzarides T. Cancer epigenetics: from mechanism to therapy. Cell. 2012;150:12–27.
   PubMed Web of Science ®Google Scholar
• Gnad F, Doll S, Manning G, et al. Bioinformatics analysis of thousands of TCGA tumors to determine the involvement of epigenetics regulators in human cancer. BMC Genomics. 2015;16(Suppl 8):S5.
   PubMedGoogle Scholar
• Kadoch C, Crabtree GR. Reversible disruption of mSWI/SNF (BAF) complexes by the SS18-SSX oncogenic fusion in synovial sarcoma. Cell. 2013 Mar 28;153(1):71–85.
   PubMed Web of Science ®Google Scholar
• Lubieniecka JM, de Bruijn DR, Su L, et al. Histone deacetylase inhibitors reverse SS18-SSX-mediated polycomb silencing of the tumor suppressor early growth response 1 in synovial sarcoma. Cancer Res. 2008 Jun 1;68(11):4303–4310.
   PubMed Web of Science ®Google Scholar
• Su L, Sampaio AV, Jones KB, et al. Deconstruction of the SS18-SSX fusion oncoprotein complex: insights into disease etiology and therapeutics. Cancer Cell. 2012;21:333–347.
   PubMed Web of Science ®Google Scholar
• Shen JK, Cote GM, Gao Y, et al. Targeting EZH2-mediated methylation of H3K27 inhibits proliferation and migration of synovial sarcoma in vitro. Sci Rep. 2016 Apr 29;6:25239.
   PubMed Web of Science ®Google Scholar
• Kadoch C, Williams RT, Calarco JP, et al. Dynamics of BAF-polycomb complex opposition on heterochromatin in normal and oncogenic states. Nat Genet. 2017 Feb;49(2):213–222.
   PubMed Web of Science ®Google Scholar
• Banito A, Li X, Laporte AN, et al. The SS18-SSX oncoprotein hijacks KDM2B-PRC1.1 to drive synovial sarcoma. Cancer Cell. 2018;33:527–541.
   PubMed Web of Science ®Google Scholar
• McBride MJ, Pulice JL, Beird HC, et al. The SS18-SSX fusion oncoprotein hijacks BAF complex targeting and function to drive synovial sarcoma. Cancer Cell. 2018 Jun;33:1–14.
   PubMed Web of Science ®Google Scholar
• Naing KW, Monjazeb AM, Li C-S, et al. Perioperative radiotherapy is associated with improved survival among patients with synovial sarcoma: A SEER analysis. J Surg Oncol. 2015;111(2):158–164.
   PubMed Web of Science ®Google Scholar
• Shi W, Indelicato DJ, Morris CG, et al. Long-term treatment outcomes for patients with synovial sarcoma: a 40-year experience at the University of Florida. Am J Clin Oncol. 2013 Feb;36(1):83–88.
   PubMed Web of Science ®Google Scholar
• Frustaci S, Gherlinzoni F, De Paoli A, et al. Adjuvant chemotherapy for adult soft tissue sarcomas of extremities and girdles: results of the Italian randomized cooperative trial. J Clin Oncol. 2001;19:1238–1247.
   PubMed Web of Science ®Google Scholar
• Spurrell EL, Fisher C, Thomas JM, et al. Prognostic factors in advanced synovial sarcoma: an analysis of 104 patients treated at the royal marsden hospital. Ann Oncol. 2005;16(3):437–444.
   PubMed Web of Science ®Google Scholar
• Eilber FC, Brennan MF, Eilber FR, et al. Chemotherapy is associated with improved survival in adult patients with primary extremity synovial sarcoma. Ann Surg. 2007;246(1):105–113.
   PubMed Web of Science ®Google Scholar
• Gronchi A, Stacchiotti S, Verderio P, et al. Short, full-dose adjuvant chemotherapy (CT) in high-risk adult soft tissue sarcomas (STS): long-term follow-up of a randomized clinical trial from the Italian sarcoma group and the Spanish sarcoma group. Ann Oncol. 2016;27(12):2283–2288.
   PubMed Web of Science ®Google Scholar
• Woll PJ, Reichardt P, Le Cesne A, et al. EORTC soft tissue and bone sarcoma group and the NCIC clinical trials group sarcoma disease site committee. adjuvant chemotherapy with doxorubicin, ifosfamide, and lenograstim for resected soft-tissue sarcoma (EORTC 62931): a multicentre randomized controlled trial. Lancet Oncol. 2012;13:1045–1105.
   PubMed Web of Science ®Google Scholar
• Pasquali S, Pizzamiglio S, Touati N, et al. The impact of chemotherapy on survival of patients with extremity and trunk wall soft tissue sarcoma: revisiting the results of the EORTC-STBSG 62931 randomised trial. Eur J Cancer. 2019;109:51–60.
   PubMed Web of Science ®Google Scholar
• Gronchi A, Ferrari S, Quagliuolo V, et al. Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001): an international, open-label, randomised, controlled, phase 3, multicentre trial. Lancet Oncol. 2017;18(6):812–822.
   PubMed Web of Science ®Google Scholar
• Casali PG, Abecassis N, Bauer S, et al. on behalf of the ESMO guidelines committee and EURACAN. Soft tissue and visceral sarcomas: ESMO-EURACAN clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29(Supplement_4):iv268–iv269.
   PubMedGoogle Scholar
• Sleijfer S, Ouali M, van Glabbeke M, et al. Prognostic and predictive factors for outcome to first-line ifosfamide-containing chemotherapy for adults patients with advanced soft tissue sarcoma: an exploratory, retrospective analysis on large series from European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC-STBSG). Eur J Cancer. 2010;46:72–83.
   PubMed Web of Science ®Google Scholar
• Eilber FC, Brennan MF, Eilber FR, et al. Chemotherapy is associated with improved survival in adult patients with primary extremity synovial sarcoma. Ann Surg. 2007;246:105–113.
   PubMed Web of Science ®Google Scholar
• Vlenterie M, Litiere S, Rizzo E, et al. Outcome of chemotherapy in advanced synovial sarcoma patients: review of 15 clinical trials from the European organisation for research and treatment of cancer soft tissue and bone sarcoma group; setting a new landmark for studies in this entity. Eur J Cancer. 2016 May;58:62–72.
   PubMed Web of Science ®Google Scholar
• Tap WD, Joner RL, Van Tine BA, et al. Olaratumab and doxorubicin versus doxorubicin alone for treatement of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial. Lancet. 2016;388:488–497.
   PubMed Web of Science ®Google Scholar
• Olaratumab for STS disappoints in phase III. Cancer Discov. 2019;9(3):312–313.
   Web of Science ®Google Scholar
• Noujaim J, Costantinidou A, Messiou C, et al. Successful of ifosfamide rechallenge in soft tissue sarcoma. Am J Clin Oncol. 2018 Feb;41(2):147–151.
   PubMed Web of Science ®Google Scholar
• Sanfilippo R, Dileo P, Blay JY, et al. Trabectedin in advanced synovial sarcoma: a multi-center retrospective study from four European institutions and the Italian rare cancer networks. Anticancer Drugs. 2015;26:678–681.
   PubMed Web of Science ®Google Scholar
• Le Cesne A, Cresta S, Maki RG, et al. A retrospective analysis of antitumor activity with trabectedin in traslocation-related sarcoma. Eur J Cancer. 2012 Nov;48(16):3036–3044.
   PubMed Web of Science ®Google Scholar
• Van der Graaf WT, Blay JY, Chawla SP, et al. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2012;379:1879–1886.
   PubMed Web of Science ®Google Scholar
• Brecht IB, Ferrari A, Int-Veen C, et al. Grossly-resected synovial sarcoma treated by the German and Italian pediatric soft tissue sarcoma cooperative group: discussion on the role of adjuvant therapies. Pediatr Blood Cancer. 2006;46:11–17.
   PubMed Web of Science ®Google Scholar
• Orbach D, Dowell HM, Rey A, et al. Sparing strategy does not compromise prognosis in pediatric localized synovial sarcoma: experience of the International society of pediatric oncology, malignant mesenchymal tumors (SIOP-MMT) working group. Pediatr Blood Cancer. 2011;57:1130–1136.
   PubMed Web of Science ®Google Scholar
• Brennan B, Stevens M, Kelsey A, et al. Synovial sarcoma in childhood and adolescence: a restrospective series of 77 patients registered by the children’s cancer and leukaemia group between 1991 and 2006. Pediatr Blood Cancer. 2010;55:85–90.
   PubMed Web of Science ®Google Scholar
• Brennan B, Stiller C, Grimer R, et al. Outcome and the effect of age and socioeconomic status in 1318 patients with synovial sarcoma in the English national cancer registry: 1985–2009. Clin Sarcoma Res. 2016 Oct 14;6:18.
   PubMed Web of Science ®Google Scholar
• Smolle MA, Parry M, Jeys L, et al. Synovial sarcoma: do children do better? Eur J Surg Oncol. 2018 Jul 20;S0748–7983(18):5–31185. pii.
   Google Scholar
• Ferrari A, Gronchi A, Casanova M, et al. Synovial sarcoma: a retrospective analysis of 271 patients of all ages treated at a single institution. Cancer. 2004;101:627–634.
   PubMed Web of Science ®Google Scholar
• Gronchi A, Casali P. Adjuvant therapy for high-risk soft tissue sarcoma in the adult. Curr Treat Options Oncol. 2013;14(3):415–424.
   PubMed Web of Science ®Google Scholar
• Baldini EH, Goldberg J, Jenner C, et al. Long-term outcomes after function-sparing surgery without radiotherapy for soft tissue sarcoma of the extremities and trunk. J Clin Oncol. 1999;17(10):3252e9.
   Web of Science ®Google Scholar
• Cahlon O, Spierer M, Brennan MF, et al. Long-term outcomes in extremity soft tissue sarcoma after a pathologically negative re-resection and without radiotherapy. Cancer. 2008;112(12):2774e9.
   Web of Science ®Google Scholar
• Ferrari A, Chi Y, De Salvo GL, et al. Surgery alone is sufficient therapy for children and adolescents with low-risk synovial sarcoma: a joint analysis from the European pediatric soft tissue sarcoma study group and children’s oncology group. Eur J Cancer. 2017;78:1–56.
   PubMed Web of Science ®Google Scholar
• Soole F, Maupain C, Defachelles AS, et al. Synovial sarcoma relapses in children and adolescents: prognostic factors, treatment and outcome. Pediatr Blood Cancer. 2014 Aug;61(8):1387–1393.
   PubMed Web of Science ®Google Scholar
• Mancuso T, Mezzekani A, Riva C, et al. Analysis of SS18-SSX fusion transcripts and bcl-2 expression phosphorylation status in synovial sarcoma. Lab Invest. 2000;80:805–813.
   PubMed Web of Science ®Google Scholar
• Kawaguchi S, Wada T, Ida K, et al. Phase I vaccination trial of SS18-SSX junction peptide in patients with disseminated synovial sarcoma. J Transl Med. 2005 Jan 12;3(1):1.
   PubMed Web of Science ®Google Scholar
• Tamborini E, Bonadiman L, Greco A, et al. Expression of ligand-activated KIT and platelet-derived growth factor receptor tyrosine kinase receptors in synovial sarcoma. Clin Cancer Res. 2004;10:938–943.
   PubMed Web of Science ®Google Scholar
• Shoffski P, Agulnik M, Stacchiotti S, et al. Phase II multi-center study of the EZH2 inhibitor tazemetostat in adults with synovial sarcoma (NCT02601950). J Clin Oncol. 2017;35(suppl; abs 11057).
   Google Scholar
• Rt N, Pulice JL, Valencia AM, et al. SMARCB1 is required for widespread BAF complex-mediated activation of enhancers and bivalent promoters. Nat Genet. 2017;49:1613–1632.
   PubMed Web of Science ®Google Scholar
• Mir O, Brodowicz T, Italiano A, et al. Safety and efficacy of regorafenib in patients with advanced soft tissue sarcoma (REGOSARC): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Oncol. 2016 Dec;17(12):1732–1742.
   PubMed Web of Science ®Google Scholar
• Brodowicz T, Mir O, Wallet J, et al. Efficacy and safety of regorafenib compared to placebo and to post-cross-over regorafenib in advanced non-adipocytic soft tissue sarcoma. Eur J Cancer. 2018;99:28–36.
   PubMed Web of Science ®Google Scholar
• Chi Y, Fang Z, Hong X, et al. Safety and efficacy of anlotinib, a multikinase angiogenesis inhibitor, in patients with refractory metastatic soft-tissue sarcoma. Clin Cancer Res. 2018 Nov 1;24(21):5233–5238.
   PubMed Web of Science ®Google Scholar
• Pollack SM, He Q, Yearley JH, et al. T-cell infiltration and clonality correlate with programmed cell death protein 1 and programmed death-ligand 1 expression in patients with soft tissue sarcomas. Cancer. 2017;123:3291–3304.
   PubMed Web of Science ®Google Scholar
• Tawbi HA, Burgess M, Bolejack V, et al. Pembrolizumab in advanced soft tissue sarcoma and bone sarcoma (SARC028): a multi-centre, two cohort, single arm, open label, phase II trial. Lancet Oncol. 2017 Dec;18(12):e711.
   PubMed Web of Science ®Google Scholar
• D’Angelo SP, Mahoney MR, Van Tine BA, et al. Nivolumab with or without impilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase II trials. Lancet Oncol. 2018 Mar;19(3):416–426.
   PubMed Web of Science ®Google Scholar
• Lai JP, Robbins PF, Raffeld M, et al. NY-ESO-1 expression in synovial sarcoma and other mesenchymal tumors: significant for NY-ESO-1 based targeted therapies and differential diagnosis. Mod Pathol. 2012 Jun;25(6):854–858.
   PubMed Web of Science ®Google Scholar
• Robbins PF, Morgan RA, Feldman SA, et al. Tumor regression in patients with metastatic synovial sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J Clin Oncol. 2011;29:917–924.
   PubMed Web of Science ®Google Scholar
• Robbins PF, Kassim SH, Tran TL, et al. A pilot trial using lymphocytes genetically engineered with NY-ESO-1 reactive T-cell receptor: long-term follow-up and correlates with response. Clin Cancer Res. 2015;21(5):1019–1027.
   PubMed Web of Science ®Google Scholar
• Somaiah N, Block MS, Kim JW, et al. Single agent LV305 to induce anti-tumor immune and clinical responses in patients with advanced or metastatic sarcoma and other cancers expressing NY-ESO-1. J Clin Oncol. 2016;34(suppl; abs 3093).
   Google Scholar
• Somaiah N, Chawla S, Block M, et al. Immune response, safety and survival impact from CMB305 in NY-ESO-1+ recurrent soft tissue sarcomas. J Clin Oncol. 2017;35(suppl; abs 11006).
   PubMedGoogle Scholar
• Pollack SM, Lu H, Gnjatic S, et al. First in human treatment with a dendritic cell targeting lenti-viral vector expressing NY-ESO-1, LV305, induces deep, durable response in refractory metastatic synovial sarcoma patient. J Immunother. 2017;40:302–306.
   PubMed Web of Science ®Google Scholar
• Casanova M, Basso E, Magni C, et al. Response to pazopanib in two pediatric patients with pretreated relapsing synovial sarcoma. Tumori. 2017 Jan 21;103(1):e1–e3.
   PubMed Web of Science ®Google Scholar
• Vassal G, Kearns P, Blanc P, et al. Orphan drug regulation: a missed opportunity for children and adolescents with cancer. Eur J Cancer. 2017;84:148–158.
   Web of Science ®Google Scholar